(Go: >> BACK << -|- >> HOME <<)

Offerings

Why GameStop Shares Are Rallying Friday
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
What's Going On With Alibaba Stock On Thursday?
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
What's Going On With Alibaba Stock On Thursday?
Popular Tech YouTuber Linus Sebastian Says Months-Long Investigation Finds Ex-Employee's Harassment Claims 'Not Substantiated'
GlobalFoundries Launches $950 Million Secondary Offering

Offerings Recent News

Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant advancements, reflecting in raised price targets.
Alzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slide
Alzemend Neuro made waves Tuesday when the company announced its decision to terminate its "at-the-market" equity offering program. Shares were down nearly 12% at last check.
UMB Financial Is Down After Largest Acquisition In Its 111-Year History - Here's Why
UMB Financial shares down after inking acquisition deal, pricing offering, and reporting Q1 FY24 results.
Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity
Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show potential for treatment with a differentiated safety profile.
Why Barnes & Noble Education Shares Are Diving Today
Barnes & Noble Education, Inc. announces a rights plan & equity investment to strengthen balance sheet. Stock down 65.7% at $0.2400.
Inovio Pharmaceuticals Stock Is Diving Today: What's Happening?
Inovio announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share.
Trump Media & Technology Group Stock Is Tumbling Monday: What's Going On?
Former President Donald Trump's Trump Media & Technology Group, which is behind the Truth Social platform, has filed for the potential issuance of up to 21.49 million shares of common stock issuable upon the exercise of warrants related to Digital World. Trump is the majority shareholder in the company.
CarMax Reacts Swiftly After Earnings Miss With $1.25B Bond Sale: Report
CarMax reportedly reacts swiftly to earnings miss with a $1.25B bond sale, aiming to address investor concerns. Mitsubishi UFJ Financial Group oversees the deal, anticipated to rise to $1.6 billion.
Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal
Eliem Therapeutics will acquire Tenet Medicines, focusing on advancing TNT119, an anti-CD19 antibody for autoimmune diseases. Strategic alternatives explored. $120 million private placement. Acquisition expected mid-2024.
Why Metal 3D Printing Technology Company Velo3D Shares Are Tumbling Today
Velo3D shares drop after announcing $12 million public offering of stock and warrants. To be used for working capital and debt repayment.
Why SoundHound AI Stock Is Moving Lower Wednesday
In a new regulatory filing, SoundHound said it entered into an equity distribution agreement in which the company may offer and sell up to $150 million of its Class A common stock from time to time in an at-the-market equity program.
Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity
Explore TARA-002's data in NMIBC treatment. Discover findings from three trials, including response rates, adverse events, and future plans. Stay updated on Protara Therapeutics' advancements in cancer therapy and FDA alignment for Choline Chloride.
What's Going On With Signet Jewelers Stock Today?
Signet Jewelers Ltd (NYSE:SIG) and Leonard Green & Partners, L.P. announce a significant strategic move, amending Series A Convertible Preference Shares to net share settlement and repurchasing half of the Preferred Shares. CEO Virginia C. Drosos emphasizes the company's robust performance, marked by double-digit revenue growth, enhanced gross margins, and a substantial increase in non-GAAP diluted earnings per share, along with significant returns to shareholders.

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers